232 related articles for article (PubMed ID: 22143063)
21. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT.
Rubio MT; Savani BN; Labopin M; Piemontese S; Polge E; Ciceri F; Bacigalupo A; Arcese W; Koc Y; Beelen D; Gülbas Z; Wu D; Santarone S; Tischer J; Afanasyev B; Schmid C; Giebel S; Mohty M; Nagler A
J Hematol Oncol; 2016 Mar; 9():25. PubMed ID: 26980295
[TBL] [Abstract][Full Text] [Related]
22. Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis.
Kharfan-Dabaja MA; Moukalled N; Reljic T; El-Asmar J; Kumar A
Hematol Oncol Stem Cell Ther; 2018 Jun; 11(2):53-64. PubMed ID: 29197550
[TBL] [Abstract][Full Text] [Related]
23. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning.
Dreger P; Brand R; Hansz J; Milligan D; Corradini P; Finke J; Deliliers GL; Martino R; Russell N; Van Biezen A; Michallet M; Niederwieser D;
Leukemia; 2003 May; 17(5):841-8. PubMed ID: 12750695
[TBL] [Abstract][Full Text] [Related]
24. An unusual presentation of a chronic lymphocytic leukemia patient with 17p deletion after reduced-intensity transplantation: Richter syndrome and concomitant graft-versus-host disease--case report.
Salihoglu A; Ozbalak M; Keskin D; Tecimer T; Soysal T; Ferhanoglu B
Transplant Proc; 2013 Sep; 45(7):2845-8. PubMed ID: 23747187
[TBL] [Abstract][Full Text] [Related]
25. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
26. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-).
Caballero D; García-Marco JA; Martino R; Mateos V; Ribera JM; Sarrá J; León A; Sanz G; de la Serna J; Cabrera R; González M; Sierra J; San Miguel J
Clin Cancer Res; 2005 Nov; 11(21):7757-63. PubMed ID: 16278397
[TBL] [Abstract][Full Text] [Related]
27. Antithymocyte globulin in reduced-intensity conditioning regimen allows a high disease-free survival exempt of long-term chronic graft-versus-host disease.
Devillier R; Fürst S; El-Cheikh J; Castagna L; Harbi S; Granata A; Crocchiolo R; Oudin C; Mohty B; Bouabdallah R; Chabannon C; Stoppa AM; Charbonnier A; Broussais-Guillaumot F; Calmels B; Lemarie C; Rey J; Vey N; Blaise D
Biol Blood Marrow Transplant; 2014 Mar; 20(3):370-4. PubMed ID: 24315846
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors to predict outcome of reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukemia.
Jindra P; Raida L; Lysak D; Karas M; Papajik T; Jungova A; Mohammadová L; Houdova L
Neoplasma; 2016; 63(4):595-600. PubMed ID: 27268923
[TBL] [Abstract][Full Text] [Related]
29. Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis.
Delgado J; Pillai S; Phillips N; Brunet S; Pratt G; Briones J; Lovell R; Martino R; Ewing J; Sureda A; Milligan DW; Sierra J
Ann Oncol; 2009 Dec; 20(12):2007-12. PubMed ID: 19596701
[TBL] [Abstract][Full Text] [Related]
30. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
31. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J; Thiede C; Bornhauser M; Schwerdtfeger R; Kiehl M; Beyer J; Sayer HG; Kroger N; Hensel M; Scheffold C; Held TK; Hoffken K; Ho AD; Kienast J; Neubauer A; Zander AR; Fauser AA; Ehninger G; Siegert W;
J Clin Oncol; 2003 Jul; 21(14):2747-53. PubMed ID: 12860954
[TBL] [Abstract][Full Text] [Related]
32. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of Patients Diagnosed With Chronic Lymphocytic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: Results From a Tertiary Care Center.
Linn SM; Nampoothiri RV; Chen C; Pasic I; Al-Shaibani Z; Lam W; Law AD; Michelis FV; Kim DDH; Gerbitz A; Lipton J; Kumar R; Mattsson J; Viswabandya A
Hematol Oncol Stem Cell Ther; 2023 Apr; 16(3):230-237. PubMed ID: 34856195
[TBL] [Abstract][Full Text] [Related]
34. [News in therapeutic management of chronic lymphoid leukemia].
Michallet AS; Salles G; Coiffier B; Michallet M
Bull Cancer; 2005 Mar; 92(3):249-56. PubMed ID: 15820919
[TBL] [Abstract][Full Text] [Related]
35. The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia.
Davids MS; Alyea EP
Curr Hematol Malig Rep; 2015 Mar; 10(1):18-27. PubMed ID: 25682168
[TBL] [Abstract][Full Text] [Related]
36. Stem cell transplantation in chronic lymphocytic leukemia.
Gribben JG
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):53-8. PubMed ID: 19147079
[TBL] [Abstract][Full Text] [Related]
37. [Allogeneic hematopoietic stem cell transplantation following reduced intensity conditioning regimen for treatment of refractory leukemia].
Jiang JL; Yan SK; Yang J; Cai Y; Wan LP; Qin YW; Wang C
Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):517-21. PubMed ID: 19112913
[TBL] [Abstract][Full Text] [Related]
38. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.
Sorror ML; Maris MB; Sandmaier BM; Storer BE; Stuart MJ; Hegenbart U; Agura E; Chauncey TR; Leis J; Pulsipher M; McSweeney P; Radich JP; Bredeson C; Bruno B; Langston A; Loken MR; Al-Ali H; Blume KG; Storb R; Maloney DG
J Clin Oncol; 2005 Jun; 23(16):3819-29. PubMed ID: 15809448
[TBL] [Abstract][Full Text] [Related]
39. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.
Kim HT; Ahn KW; Hu ZH; Davids MS; Volpe VO; Antin JH; Sorror ML; Shadman M; Press O; Pidala J; Hogan W; Negrin R; Devine S; Uberti J; Agura E; Nash R; Mehta J; McGuirk J; Forman S; Langston A; Giralt SA; Perales MA; Battiwalla M; Hale GA; Gale RP; Marks DI; Hamadani M; Ganguly S; Bacher U; Lazarus H; Reshef R; Hildebrandt GC; Inamoto Y; Cahn JY; Solh M; Kharfan-Dabaja MA; Ghosh N; Saad A; Aljurf M; Schouten HC; Hill BT; Pawarode A; Kindwall-Keller T; Saba N; Copelan EA; Nathan S; Beitinjaneh A; Savani BN; Cerny J; Grunwald MR; Yared J; Wirk BM; Nishihori T; Chhabra S; Olsson RF; Bashey A; Gergis U; Popat U; Sobecks R; Alyea E; Saber W; Brown JR
Clin Cancer Res; 2019 Aug; 25(16):5143-5155. PubMed ID: 31253630
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]